Cullinan Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the fiscal quarter ended September 30, 2025, an officer (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K. The trading plan is intended to satisfy the affirmative defense in Rule 10b5-1(c). The material terms of such trading arrangement are described below.
Jennifer Michaelson, Ph.D., Chief Scientific Officer
On August 7, 2025, Jennifer Michaelson, Ph.D., our Chief Scientific Officer, entered into a Rule 10b5-1 trading arrangement that provides that Dr. Michaelson, acting through a broker, may sell up to an aggregate of 83,606 shares of our common stock. Sales of shares under the trading arrangement will not begin until the applicable Rule 10b5-1 “cooling-off” period has expired and are scheduled to end by May 1, 2027, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Michaelson or the broker, or as otherwise provided in the arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.